← Evidence map

ArticleFrontiers in oncology2025

Remarkable response to CDK4/6 inhibitor-based endocrine therapy in HR+/HER2- metastatic male breast cancer with visceral crisis: a case report.

Jianfeng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Remarkable response to CDK4/6 inhibitor-based endocrine therapy in HR+/HER2- metastatic male breast cancer with visceral crisis: a case report. | Socratic